<code id='614D4ED432'></code><style id='614D4ED432'></style>
    • <acronym id='614D4ED432'></acronym>
      <center id='614D4ED432'><center id='614D4ED432'><tfoot id='614D4ED432'></tfoot></center><abbr id='614D4ED432'><dir id='614D4ED432'><tfoot id='614D4ED432'></tfoot><noframes id='614D4ED432'>

    • <optgroup id='614D4ED432'><strike id='614D4ED432'><sup id='614D4ED432'></sup></strike><code id='614D4ED432'></code></optgroup>
        1. <b id='614D4ED432'><label id='614D4ED432'><select id='614D4ED432'><dt id='614D4ED432'><span id='614D4ED432'></span></dt></select></label></b><u id='614D4ED432'></u>
          <i id='614D4ED432'><strike id='614D4ED432'><tt id='614D4ED432'><pre id='614D4ED432'></pre></tt></strike></i>

          leisure time

          leisure time

          author:entertainment    Page View:236
          AI skin cancer detector, dermasensor. -- health tech coverage from STAT
          Around 5 million skin cancers are diagnosed each year in the United States. Skin cancer is common, but it’s also not that deadly when caught early. Courtesy DermaSensor

          The Food and Drug Administration cleared an AI-powered device for detecting skin cancer on Wednesday, giving primary care physicians a new way to evaluate troubling skin spots.

          Around 5 million skin cancers are diagnosed each year in the United States. Skin cancer is common, but most types are not that deadly when caught early.

          advertisement

          The device, developed by a small company called DermaSensor, is handheld and uses light to examine suspicious moles on a cellular level. It will be marketed specifically for primary care physicians to use in routine check-ups in patients aged 40 and above.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more
          Merck, Daiichi strike cancer drug pact worth up to $22 billion
          Merck, Daiichi strike cancer drug pact worth up to $22 billion

          KenaBetancur/GettyImagesMADRID—MerckispayingbillionsofdollarstopartnerwithDaiichiSankyoonaseriesofca

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          STAT Summit: The economic case for universal basic health care

          MITeconomistAmyFinkelsteinchatswithSTAT'sBobHermanatthe2023STATSummit.STATFixingtheU.S.healthcaresys